TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Investing.com - Guggenheim has reiterated its Buy rating and $92.00 price target on Dianthus Therapeutics (NASDAQ:DNTH), currently trading at $20.85, ahead of upcoming clinical trial results expected next month. The stock has shown strong momentum with an 8.88% gain over the past week, and analysts maintain a highly bullish consensus on the company according to InvestingPro data.
The research firm maintains DNTH as one of its "Top Picks for 2025" while highlighting an "asymmetric risk/reward (+100%/-50%)" opportunity for the stock as the company approaches a key data readout for its generalized Myasthenia Gravis (gMG) treatment. The company’s strong financial position is evidenced by its robust current ratio of 13.12 and minimal debt levels.
Guggenheim’s analysis of placebo response rates from 12 recent Phase II/III gMG studies suggests DNTH’s Phase II MaGic trial could see placebo responses of approximately 1.7-2.3 point reductions in MG-ADL scores from baseline, which the firm believes leaves sufficient room for demonstrating statistically significant treatment effects.
The research note indicates that historical active treatment arms have achieved up to 4.4 point drops in MG-ADL scores in gMG trials with complement inhibitors, suggesting that a placebo-adjusted difference of 1.8 points or greater is attainable and "should be well-received by the Street."
Guggenheim believes the gMG opportunity for Dianthus Therapeutics "remains largely underappreciated at the current share price," with the Phase II MaGic trial results expected to be released in September. With a market capitalization of $671 million, InvestingPro analysis suggests the stock is currently trading below its Fair Value, with 6 additional exclusive insights available for subscribers.
In other recent news, The Oncology Institute announced that Anne McGeorge will become the new Chairman of the Board, effective August 2025. McGeorge, who has been on the board since 2021, brings extensive healthcare financial experience, having previously led Grant Thornton LLP’s Global Health Care and Life Sciences Practice. Meanwhile, Dianthus Therapeutics is preparing to release Phase II trial data for its treatment DNTH103 in generalized myasthenia gravis this September. Guggenheim has raised its price target for Dianthus Therapeutics to $92.00, maintaining a Buy rating ahead of this significant clinical readout. Stifel also reiterated its Buy rating with a $52.00 price target, highlighting the importance of the upcoming data for the company. In addition, William Blair initiated coverage on Dianthus Therapeutics with an Outperform rating, assigning a fair value of $47.57 per share. This marks the 13th Buy rating for Dianthus, further emphasizing investor interest in its clinical developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.